LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab (Primary) ; Favezelimab/pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary) ; Vibostolimab (Primary)
Indications Hodgkin's disease; Malignant melanoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms LIGHTBEAM-U01
Sponsors Merck Sharp & Dohme

Most Recent Events

03 Mar 2025 Planned initiation date changed from 13 Dec 2024 to 15 Jan 2025.
16 Jan 2025 Status changed from recruiting to withdrawn prior to enrolment.
10 Dec 2024 Planned initiation date changed from 14 Nov 2024 to 13 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight